As adoption and adherence grows, plan sponsors are keeping a close watch on clinical benefits and long-term financial impact
Others claim they no longer need exercise
Time to Steady State As a general pharmacological principle, steady state is typically achieved after approximately 45 half-lives of regular dosing
One vial, one reconstitution, full dissolution
10.1038/onc.2017.38 Summary Keywords alcohol-associated liver disease (ALD), glucagon-like peptide 1 receptor agonists (GLP-1 RAs), metabolic dysfunction and alcohol-associated liver disease (MetALD), metabolic dysfunction-associated steatotic liver disease (MASLD), steatotic liver disease (SLD) Citation Mahalingam S, Kharbanda KK, Casey CA and Rasineni K (2026) Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum